Abstract
The brain is second only to the liver as a source of apolipoprotein E (APOE for gene; ApoE for protein), a protein which is intricately involved in lipid transport and metabolism. Following genetic linkage of late-onset familial Alzheimer’s disease to chromosome 19 and the identification of ApoE in senile plaques, neurofibrillary tangles and amyloid-laden blood vessels, over-representation of the APOE ε4 allele was recognized in both familial late-onset and sporadic Alzheimer’s disease. A dose-dependent association of the APOE ε4 allele with increasing cerebrovascular amyloid β-protein deposition was subsequently identified. Lobar hemorrhage is the major clinical manifestation of cerebral amyloid angiopathy (CAA) and is thought to follow the development of CAA-associated vasculopathic complications such as fibrinoid necrosis and concentric (“double barrel”) blood vessel formation. There is emerging a complex relationship between APOE ε4, APOE ε2 and hemorrhage associated with CAA. For example, pathological studies have demonstrated that the APOE ε2 allele, the least frequent of the APOE alleles, is over-represented in patients with CAA-related hemorrhage. This is also true for patients with co-existing Alzheimer’s disease, who otherwise have a very low ε2 allele frequency. Other forms of intracranial hemorrhage (hypertensive and subarachnoid hemorrhage) do not share the same association with APOE ε2. Patients with the ε2 allele and CAA-related hemorrhage are more likely to have taken anticoagulant or antiplatelet medication, have had hypertension or minor head trauma than non-ε2 carriers. In addition, there is now evidence suggesting that the ε2 allele enhances CAA-associated vasculopathic changes such as fibrinoid necrosis or concentric blood vessel formation. The role of APOE in other manifestations of CAA, including leukoencephalopathy and transient neurological deficits, is currently unclear. Besides being a risk factor for Alzheimer’s disease, CAA and CAA-related hemorrhage, APOE genotype can also influence outcome following acute brain injury. By an as yet unidentified mechanism the ε4 allele is a marker of poor prognosis after head injury and intracerebral hemorrhage. Study of APOE has provided useful insights into the pathogenetic steps leading to CAA and CAA-related hemorrhage. Its influence on CAA and outcome from acute brain injury tantalizingly offers new prospects for future therapeutic interventions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Goate, A., Chartier-Harlin, M.C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349, 704–706.
Chartier-Harlin, M.C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., Hardy, J. (1991) Early-onset Alzheimer’s disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 353, 844–846.
Hendriks, L. van, D.C., Cras, P., Cruts, M., Van, H.W., van, H.F., Warren, A., McInnis, M.G., Antonarakis, S.E., Martin, J.J. (1992) Presenile dementia and cerebral hemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nature Genet. 1 218–221.
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., Lannfelt, L. (1992) A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of beta-amyloid. Nature Genet. 1, 345–347.
Sherrington, R., Rogaev, E.I., Liang, Y., Rogaeva, E.A., Levesque, Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 375, 754–760.
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, DM, Oshima, J., Pettingell, W.H., Yu, C.E., Jondro, P.D., Schmidt, S.D., Wang, K., et, al (1995) Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 269, 973–977.
Lendon, C.L., Ashall, F., Goate, A.M. (1997) Exploring the etiology of Alzheimer disease using molecular genetics. JAMA 277, 825–831.
Benson, M.D. (1996) Leptomeningeal amyloid and variant transthyretins. Am. J. Pathol. 148, 351–354.
Ghetti, B., Piccardo, P., Frangione, B., Bugiani, O., Giaccone, Young, K., Prelli, F., Farlow, M.R., Dlouhy, S.R., Tagliavini, F. (1996) Prion protein amyloidosis. Brain Pathol. 6, 127–145.
Wenham, P.R., Price, W.H., Blandell, G. (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet, 337 1158–1159.
Davignon, J., Gregg, R.E., Sing, C.F. (1988) Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8, 1–21.
Schachter, F., Faure-Delanef, L., Guenot, F., Rouger, H., Froguel, P., Lesueur-Ginot, L., Cohen, D. (1994) Genetic associations with human longevity at the APOE and ACE loci. Nature Genet. 6, 29–32.
Weisgraber, K.H. (1994) Apolipoprotein E: structure-function relationships. Adv. Prot. Chem. 45, 249–302.
Weisgraber, K.H., Mahley, R.W. (1996) Human apolipoprotein E: the Alzheimer’s disease connection. FASEBJ. 10, 1485–1494.
Elshourbagy, N.A., Liao, W.S., Mahley, R.W., Taylor, J.M. (1985) Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc. Natl. Acad. Sci. USA 82, 203–207.
Pericak-Vance, M.A., Bebout, J.L., Gaskell, P.C., Jr, Yamaoka, L.H., Hung, W.Y., Alberts, M.J., Walker, A.P., Bartlett, R.J., Haynes, C.A., Welsh, K.A. (1991) Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. Am. J. Hum. Genet. 48, 1034–1050.
Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G.S., Roses, A.D. (1993) Apolipoprotein E: high-avidity binding to betaamyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 1977–1981.
Namba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., Ikeda, K. (1991) Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541, 163–166.
Saunders, A.M., Strittmatter, W.J., Schmechel, D., George, H., PH, Pericak-Vance, M.A., Joo, S.H., Rosi, B.L., Gusella, J.F., Crapper, M.L., DR, Alberts, M.J. (1993) Association of apolipoprotein E allele c4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43, 1467–1472.
Farrer, L.A., Cupples, L.A., Haines, J.L., Hyman, B., Kukull, W.A., Mayeux, R., Myers, R.H., Pericak-Vance, M.A., Risch, N., van, D.C. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349–1356.
Meyer, M.R., Tschanz, J.T., Norton, M.C., Welshbohmer, K.A., Steffens, D.C., Wyse, B.W., Breitner, J.S. (1998) APOE genotype predicts when-not whether-one is predisposed to develop Alzheimer disease. Nature Genet. 19, 321–322.
Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, GW, Roses, A.D., Haines, J.L., Pericak-Vance, M.A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921–923.
Slooter, A.J.C., Cruts, M., Kalmijn, S., Hofman, A., Breteler, M.M.B., Vanbroeckhoven, C., Vanduijn, C.M. (1998) Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam study. Arch. Neurol. 55, 964–968.
Corder, E.H., Saunders, A.M., Risch, N.J., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C.J., Rimmler, J.B., Locke, P.A., Conneally, P.M., Schmader, K.E. (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genet. 7, 180–184.
Vonsattel, J.P., Myers, R.H., Hedley-Whyte, E.T., Ropper, A.H., Bird, ED, Richardson, E.P., Jr. (1991) Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann. Neurol. 30, 637–649.
Vinters, H.V., Gilbert, J.J. (1983) Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke 14, 924–928.
Schmechel, D.E., Saunders, A.M., Strittmatter, W.J., Crain, B.J., Hulette, C.M., Joo, S.H., Pericak-Vance, M.A., Goldgaber, D., Roses, A.D. (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 9649–9653.
Premkumar, D.R., Cohen, D.L., Hedera, P., Friedland, R.P., Kalaria, RN (1996) Apolipoprotein E-64 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer’s disease. Am. J. Pathol. 148, 2083–2095.
Olichney, J.M., Hansen, L.A., Galasko, D., Saitoh, T., Hofstetter, CR, Katzman, R., Thal, L.J. (1996) The apolipoprotein E 64 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer’s disease and Lewy body variant. Neurology 47, 190–196.
Greenberg, S.M., Rebeck, G.W., Vonsattel, J.P., Gomez-Isla, T., Hyman, B.T. (1995) Apolipoprotein E 64 and cerebral hemorrhage associated with amyloid angiopathy. Ann. Neurol. 38, 254–259.
Itoh, Y., Yamada, M., Suematsu, N., Matsushita, M., Otomo, E. (1996) Influence of apolipoprotein E genotype on cerebral amyloid angiopathy in the elderly. Stroke 27, 216218.
Yamada, M., Itoh, Y., Suematsu, N., Matsushita, M., Otomo, E. (1996) Lack of an association between apolipoprotein E 64 and cerebral amyloid angiopathy in elderly Japanese. Ann. Neurol. 39, 683–684.
Yamada, M., Tsukagoshi, H., Otomo, E., Hayakawa, M. (1987) Cerebral amyloid angiopathy in the aged. J. Neurol. 234, 371–376.
Yamada, M., Sodeyama, N., Itoh, Y., Suematsu, N., Otomo, E., Matsushita, M., Mizusawa, H. (1998) Association of alphal-antichymotrypsin polymorphism with cerebral amyloid angiopathy. Ann. Neurol. 44, 129–131.
Lemere, C.A., Blusztajn, J.K., Yamaguchi, H., Wisniewski, T., Saido, T.C., Selkoe, D.J. (1996) Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3, 16–32.
Yamaguchi, H., Ishiguro, K., Sugihara, S., Nakazato, Y., Kawarabayashi, T., Sun, X., Hirai, S. (1994) Presence of apolipoprotein E on extracellular neurofibrillary tangles and on meningeal blood vessels precedes the Alzheimer beta-amyloid deposition. Acta Neuropathol. 88, 413–419.
Yamaguchi, H., Yamazaki, T., Lemere, C.A., Frosch, M.P., Selkoe, D.J. (1992) Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer’s disease. An immunoelectron microscopic study. Am. J. Pathol. 141, 249–259.
Prior, R., D’Urso, D., Frank, R., Prikulis, I., Pavlakovic, G. (1995) Experimental deposition of Alzheimer amyloid beta-protein in canine leptomeningeal vessels. Neuroreport 6, 1747–1751.
Bales, K.R., Verina, T., Dodel, R.C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E.M., Little, S.P., Cummins, D.J., Piccardo, P., Ghetti, B., Paul, S.M. (1997) Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nature Genet. 17, 263–264.
Strittmatter, W.J., Weisgraber, K.H., Huang, D.Y., Dong, L.M., Salvesen, G.S., PericakVance, M., Schmechel, D., Saunders, A.M., Goldgaber, D., Roses, A.D. (1993) Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 8098–8102.
LaDu, M.J., Falduto, M.T., Manelli, A.M., Reardon, C.A., Getz, G.S., Frail, D.E. (1994) Isoform-specific binding of apolipoprotein E to beta-amyloid. J. Biol. Chem. 269, 2340323406.
Naslund, J., Thyberg, J., Tjernberg, L.O., Wernstedt, C., Karlstrom, A.R., Bogdanovic, N., Gandy, S.E., Lannfelt, L., Terenius, L., Nordstedt (1995) Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer’s disease brain. Neuron 15, 219–228.
Small,D.A., Weisgraber, K.H., Russell, Si., Mahley, R.W., Huang, D., Saunders, A., Schmechel, D., Wisniewski, T., Frangione, B., Roses, A.D. (1994) Apolipoprotein E associates with beta amyloid peptide of Alzheimer’s disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J. Clin. Invest. 94 860–869.
Ma, J. Yee, A., Brewer, H.B.J., Das, S., Potter, H. (1994) Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372 92–94.
Castano, E.M., Prelli, F., Wisniewski, T., Golabek, A., Kumar, R.A., Soto, C., Frangione, B. (1995) Fibrillogenesis in Alzheimer’s disease of amyloid beta peptides and apolipoprotein E. Biochem. J. 306, 599–604.
Golabek, A.A., Soto, C., Vogel, T., Wisniewski, T. (1996) The interaction between apolipoprotein E and Alzheimer’s amyloid beta-peptide is dependent on beta-peptide conformation. J. Biol. Chem. 271, 10602–10606.
Naiki, H., Gejyo, F., Nakakuki, K. (1997) Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer’s beta-amyloid fibril formation in vitro. Biochemistry 36, 6243–6250.
Beffert, U., Poirier, J. (1998) ApoE associated with lipid has a reduced capacity to inhibit 13-amyloid fibril formation. Neuroreport 9, 3321–3323.
Alonzo, N.C., Hyman, B.T., Rebeck, G.W., Greenberg, S.M. (1998) Progression of cerebral amyloid angiopathy–accumulation of amyloid-beta 40 in affected vessels. J. Neuropathol. Exp. Neurol. 57, 353–359.
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., Ihara, Y. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta: evidence that an initially deposited species is A beta 42(43). Neuron 13, 45–53.
Gravina, S.A., Ho, L., Eckman, C.B., Long, K.E., Otvos, L., Jr., Younkin, L.H., Suzuki, N., Younkin, S.G. (1995) Amyloid beta protein (A beta) in Alzheimer’s disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J. Biol. Chem. 270, 7013–7016.
Iwatsubo, T., Mann, D.M., Odaka, A., Suzuki, N., Ihara, Y. (1995) Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann. Neurol. 37, 294–299.
Urmoneit, B., Prikulis, I., Wihl, G., D’Urso, D., Frank, R., Heeren, J., Beisiegel, U., Prior, R. (1997) Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Lab. Invest. 77, 157–166.
Iwamoto, N., Ishihara, T., Ito, H., Uchino, F. (1993) Morphological evaluation of amyloid-laden arteries in leptomeninges, cortices and subcortices in cerebral amyloid angiopathy with subcortical hemorrhage. Acta Neuropathol. 86, 418–421.
Mandybur, T.I. (1986) Cerebral amyloid angiopathy: the vascular pathology and complications. J. Neuropathol. Exp. Neurol. 45, 79–90.
Prior, R., D’Urso, D., Frank, R., Prikulis, I., Pavlakovic, G. (1996) Loss of vessel wall viability in cerebral amyloid angiopathy. Neuroreport 7, 562–564.
Vinters, H.V. (1987) Cerebral amyloid angiopathy. A critical review. Stroke 18, 311–324.
Nicoll, J.A., Burnett, C., Love, S., Graham, D.I., Ironside, J.W., Vinters, H.V. (1996) High frequency of apolipoprotein E e2 in patients with cerebral hemorrhage due to cerebral amyloid angiopathy. Ann. Neurol. 39, 682–683.
Kalaria, R.N., Premkumar, D.R. (1995) Apolipoprotein E genotype and cerebral amyloid angiopathy. Lancet 346, 1424
Nicoll, J.A., Burnett, C., Love, S., Graham, D.I., Dewar, D., Ironside, J.W., Stewart, J., Vinters, H.V. (1997) High frequency of apolipoprotein E c2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann. Neurol. 41, 716–721.
McCarron, M.O., Nicoll, J.A.R. (1998) High frequency of apolipoprotein E c2 allele is specific for patients with cerebral amyloid angiopathy-related hemorrhage. Neurosci. Lett. 247, 45–48.
Greenberg, S.M. (1998) Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. Neurology 51, 690–694.
Greenberg, S.M., Hyman, B.T. (1997) Cerebral amyloid angiopathy and apolipoprotein E: bad news for the good allele? Ann. Neurol. 41, 701–702.
Greenberg, S.M., Vonsattel, J.G., Segal, A.Z., Chiu, R.I., Clatworthy, A.E., Liao, A., Hyman, B.T., Rebeck, G.W. (1998) Association of apolipoprotein E e2 and vasculopathy in cerebral amyloid angiopathy. Neurology 50, 961–965.
Greenberg, S.M., Briggs, M.E., Hyman, B.T., Kokoris, G.J., Takis, C., Kanter, D.S., Kase, C.S., Pessin, M.S. (1996) Apolipoprotein E c4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke 27, 1333–1337.
McCarron, M.O., Nicoll, J.A.R., Ironside, J.W., Love, S., Alberts, M.J., Bone, I. (1999) Cerebral amyloid angiopathy-related hemorrhage: interaction of apolipoprotein E c2 with putative clinical risk factors. Submitted.
Silbert, P.L., Bartleson, J.D., Miller, G.M., Parisi, J.E., Goldman, M.S., Meyer, F.B. (1995) Cortical petechial hemorrhage, leukoencephalopathy, and subacute dementia associated with seizures due to cerebral amyloid angiopathy. Mayo Clin. Proc. 70, 477480.
O’Donnell, H.C., Rosand, J., Chiu, R.I., Furie, K.L., Ikeda, D., Greenberg, S.M. (1999) Apolipoprotein E genotype predicts hemorrhage recurrence in cerebral amyloid angiopathy. Stroke, 30 255–255. (Abstract)
Jellinger, K. (1977) Cerebrovascular amyloidosis with cerebral hemorrhage. J. Neurol. 214, 195–206.
Okazaki, H., Reagan, T.J., Campbell, R.J. (1979) Clinicopathologic studies of primary cerebral amyloid angiopathy. Mayo Clin. Proc. 54, 22–31.
Ferreiro, J.A., Ansbacher, L.E., Vinters, H.V. (1989) Stroke related to cerebral amyloid angiopathy: the significance of systemic vascular disease. J. Neurol. 236, 267–272.
Greene, G.M., Godersky, J.C., Biller, J., Hart, M.N., Adams, H.P., Jr. (1990) Surgical experience with cerebral amyloid angiopathy. Stroke 21, 1545–1549.
Smith, D.B., Hitchcock, M., Philpott, P.J. (1985) Cerebral amyloid angiopathy presenting as transient ischemic attacks. Case report. J. Neurosurg. 63, 963–964.
Anonymous (1996) Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 22–1996. Cerebral hemorrhage in a 69-year-old woman receiving warfarin. New Engl. J. Med. 335, 189–196.
Leblanc, R., Haddad, G., Robitaille, Y. (1992) Cerebral hemorrhage from amyloid angiopathy and coronary thrombolysis. Neurosurgery 31, 586–590.
Sloan, M.A., Price, T.R., Petito, C.K., Randall, A.M., Solomon, R.E., Terrin, M.L., Gore, Collen, D., Kleiman, N., Feit, F. (1995) Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience. Neurology 45, 649–658.
McCarron, M.O., Nicoll, J.A.R., Stewart, J., Ironside, J.W., Mann, D.M.A., Love, S., Graham, D.I., Dewar, D. (1998) The apolipoprotein E e2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. Submitted.
Gray, F., Dubas, F., Roullet, E., Escourolle, R. (1985) Leukoencephalopathy in diffuse hemorrhagic cerebral amyloid angiopathy. Ann. Neurol. 18, 54–59.
Greenberg, S.M., Vonsattel, J.P., Stakes, J.W., Gruber, M., Finklestein, S.P. (1993) The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage. Neurology 43, 2073–2079.
Shimode, K., Kobayashi, S., Imaoka, K., Umegae, N., Nagai, A. (1996) Leukoencephalopathy-related cerebral amyloid angiopathy with cystatin C deposition. Stroke 27, 1417–1419.
Cosgrove, G.R., Leblanc, R., Meagher-Villemure, K., Ethier, R. (1985) Cerebral amyloid angiopathy. Neurology 35, 625–631.
St George-Hyslop, P., McLachlan, D.C., Tsuda, Rogaev, E., Karlinsky, H., Lippa, C.F., Pollen, D., Tuda, T. (1994) Alzheimer’s disease and possible gene interaction. Science 263, 537
Nacmias, B., Latorraca, S., Piersanti, P., Forleo, P., Piacentini, S., Bracco, L., Amaducci, L., Sorbi, S. (1995) ApoE genotype and familial Alzheimer’s disease: a possible influence on age of onset in APP717 ValIle mutated families. Neurosci. Lett. 183, 1–3.
Sorbi, S., Nacmias, B., Forleo, P., Piacentini, S., Latorraca, S., Amaducci, L. (1995) Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer’s disease. Ann. Neurol. 38, 124–127.
Mann, D.M., Iwatsubo, T., Ihara, Y., Cairns, N.J., Lantos, P.L., Bogdanovic, N., Lannfelt, L., Winblad, B., Maat-Schieman, M.L., Rossor, M.N. (1996) Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer’s disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am. J. Pathol. 148, 1257–1266.
Haan, J., Van, B.C., van, D.C., Voorhoeve, E., van, H.F., van, S.J., Maat-Schieman, M.L., Roos, RA, Bakker, E. (1994) The apolipoprotein E e4 allele does not influence the clinical expression of the amyloid precursor protein gene codon 693 or 692 mutations. Ann. Neurol. 36, 434–437.
Haan, J., Roos, R.A., Bakker, E. (1995) No protective effect of apolipoprotein E e2 allele in Dutch hereditary cerebral amyloid angiopathy. Ann. Neurol. 37, 282
Schupf, N., Kapell, D., Lee, J.H., Zigman, W., Canto, B., Tycko, B., Mayeux, R. (1996) Onset of dementia is associated with apolipoprotein E c4 in Down’s syndrome. Ann. Neurol. 40, 799–801.
Alexander, G.E., Saunders, A.M., Szczepanik, J., Strassburger, T.L., Pietrini, P., Dani, A., Furey, M.L., Mentis, M.J., Roses, A.D., Rapoport, S.I., Schapiro, M.B. (1997) Relation of age and apolipoprotein E to cognitive function in Down syndrome adults. Neuroreport 8, 1835–1840.
Del, B.R., Comi, G.P., Bresolin, N., Castelli, E., Conti, E., Degiuli, A., Ausenda, CD, Scarlato, G. (1997) The apolipoprotein E e4 allele causes a faster decline of cognitive performances in Down’s syndrome subjects. J. Neurol. Sci. 145, 87–91.
Schupf, N., Kapell, D., Nightingale, B., Rodriguez, A., Tycko, B., Mayeux, R. (1998) Earlier onset of Alzheimer’s disease in men with Down syndrome. Neurology 50, 991–995.
Prasher, V.P., Farrer, M.J., Kessling, A.M., Fisher, E.M., West, R.J., Barber, P.C., Butler, A.C. (1998) Molecular mapping of Alzheimer-type dementia in Down’s syndrome. Ann. Neurol. 43, 380–383.
Belza, M.G., Urich, H. (1986) Cerebral amyloid angiopathy in Down’s syndrome. Clin. Neuropathol. 5, 257–260.
Anonymous (1990) Congophilic angiopathy. New York State J. Med. 90, 64–68.
Donahue, J.E., Khurana, J.S., Adelman, L.S. (1998) Intracerebral hemorrhage in two patients with Down’s syndrome and cerebral amyloid angiopathy. Acta Neuropathol. 95, 213–216.
McCarron, M.O., Nicoll, J.R., Graham, D.I. (1998) A quartet of Down’s syndrome, Alzheimer’s disease, cerebral amyloid angiopathy, and cerebral hemorrhage–interacting genetic risk factors. J. Neurol. Neurosurg. Psych. 65, 405–406.
Nicoll, J.A., Roberts, G.W., Graham, D.I. (1995) Apolipoprotein E e4 allele is associated with deposition of amyloid beta-protein following head injury. Nat. Med. 1, 135–137.
Sorbi, S., Nacmias, N., Piacentini, S., Repice, A., Latorraca, S., Forleo, P., Amaducci, L. (1995) ApoE as a prognostic factor for post-traumatic coma. Nat. Med. 1, 852
Alberts, M.J., Graffagnino, C., McClenny, C., DeLong, D., Strittmatter, W., Saunders, A.M., Roses, A.D. (1995) ApoE genotype and survival from intracerebral hemorrhage. Lancet 346, 575
Teasdale, G.M., Nicoll, J.R., Murray, G., Fiddes, M. (1997) Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 350, 1069–1071.
Laskowitz, D.T., Horsburgh, K., Roses, A.D. (1998) Apolipoprotein E and the CNS response to injury. J Cerebr. Blood F. Met. 18, 465–471.
McCarron, M.O., Muir, K.W., Weir, C.J., Dyker, A.G., Bone, 1., Nicoll, J.A.R., Lees, K.R. (1998) The apolipoprotein E e4 allele and outcome in cerebrovascular disease. Stroke 29, 1882–1887.
Masliah, E., Mallory, M., Alford, M., Ge, N., Mucke, L. (1995) Abnormal synaptic regeneration in hAPP695 transgenic and APOE knockout mice, in K. Iqbal, J.A. Mortimer, B. Winblad,, H.M. Wisniewski (eds.), Research advances in Alzheimer’s disease and related disorders, John Wiley, Sons, Chichester, New York, Brisbane, Toronto, Singapore, pp. 405–414.
Chen, Y., Lomnitski, L., Michaelson, D.M., Shohami, E. (1997) Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury. Neuroscience 80, 1255–1262.
Laskowitz, D.T., Sheng, H., Bart, R.D., Joyner, K.A., Roses, A.D., Warner, D.S. (1997) Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia. J. Cerebr. Blood F. Met. 17, 753–758.
Horsburgh, K., Kelly, S., McCulloch, J., Higgins, G.A., Roses A.D.,, Nicoll, J.A.R. (1999) Increased neuronal damage in apolipoprotein E deficient mice following global ischaemia. Neuroreport (in press).
Miyata, M., Smith, J.D. (1996) Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat. Gen. 14, 55–61.
Laskowitz, D.T. Matthew, W.D., Bennett, E.R., Schmechel, D., Herbstreith, M.H., Goel, S., Mcmillian, M.K. (1998) Endogenous apolipoprotein E suppresses LPS-stimulated microglial nitric oxide production. Neuroreport 9 615–618.
Laskowitz, D.T., Goel, S., Bennett, E.R., Matthew, W.D. (1997) Apolipoprotein E suppresses glial cell secretion of TNF-alpha. J. Neuroimmunol. 76, 70–74.
Nathan, B.P. Bellosta, S., Sanan, D.A., Weisgraber, K.H., Mahley, RW, Pitas, R.E. (1994) Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264 850–852.
Muller, W., Meske, V., Berlin, K., Scharnagl, H., Marz, W., Ohm, TG (1998) Apolipoprotein E isoforms increase intracellular CAz+ differentially through a w-agatoxin IVa-sensitive CAz+-channel. Brain Pathol. 8, 641–653.
McCarron, M.O., Hoffmann, K.L., DeLong, D.M., Gray, L., Saunders, A.M., Alberts, M.J. (1998) Intracerebral hemorrhage outcome: APOE, haematoma and oedema volumes. Submitted.
Thrift, A.G., Dorman, G.A., McNeil, J.J. (1995) Epidemiology of intracerebral hemorrhage. Epidemiol. Rev. 17, 361–381.
Rosenthal, N., Schwartz, R.S. (1998) In search of perverse polymorphisms. New Engl. J. Med. 338, 122–124.
Blacker, D., Wilcox, M.A., Laird, N.M., Rodes, L., Horvath, S.M., Go, RCP, Perry, R., Watson, B., Bassett, S.S., McInnis, M.G., Albert, M.S., Hyman, B.T., Tanzi, R.E. (1998) Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat. Genet. 19, 357–360.
Kang, D.E., Saitoh, T., Chen, X., Xia, Y., Masliah, E., Hansen, L.A., Thomas, R.G., Thal, L.J., Katzman, R. (1997) Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer’s disease. Neurology 49, 56–61.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
McCarron, M.O., Nicoll, J.A.R. (2000). APOE Genotype in Relation to Sporadic and Alzheimer-Related CAA. In: Verbeek, M.M., de Waal, R.M.W., Vinters, H.V. (eds) Cerebral Amyloid Angiopathy in Alzheimer’s Disease and Related Disorders. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-1007-7_5
Download citation
DOI: https://doi.org/10.1007/978-94-017-1007-7_5
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-5480-7
Online ISBN: 978-94-017-1007-7
eBook Packages: Springer Book Archive